S.A. Mason’s BioCryst Pharmaceuticals BCRX Stock Holding History

S.A. Mason’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-250	Closed	-$1K	–	291
2020 Q1	$1K	Hold	250	–	–	﹤0.01%	375
2019 Q4	$1K	Buy	+250	New	+$629	﹤0.01%	435

Other funds holding BCRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

S.A. Mason's BCRX Position: Q2 2020 in Review

S.A. Mason sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2020, closing a stake of 250 shares — an estimated $1K sold.

S.A. Mason first reported a position in BCRX in Q4 2019 and held it in 2 quarters. The position peaked at $1K in Q1 2020. 165 funds tracked by Wall St. Rank hold BCRX as of Q2 2020.

S.A. Mason reported no remaining BioCryst Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
S.A. Mason sold 250 BioCryst Pharmaceuticals shares in Q2 2020, an estimated $1K.
S.A. Mason first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 2 quarters.
S.A. Mason's BioCryst Pharmaceuticals position peaked at $1K in Q1 2020.
165 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2020.

Based on S.A. Mason's 13F filing for Q2 2020, filed 27 Jul 2020.